Market Cap ₹8188 Cr.
Stock P/E -15.3
P/B 2.3
Current Price ₹533.8
Book Value ₹ 229.4
Face Value 5
52W High ₹630
Dividend Yield 0%
52W Low ₹ 167
Wockhardt Ltd is a pharmaceutical and biotechnology company. The Company's agencies include manufacture and advertising of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines. It manufactures a range of dosage forms, such as sterile injectables and lyophilized merchandise. The Company gives products in therapeutic areas of dermatology, cosmeceuticals, oncology, medical vitamins, osteoarthritis, ache management, nephrology, cough therapy and diabetology. The Company’s merchandise throughout India includes Citawok, Citawok Forte, Citawok Plus, Emrok, Emrok O, Erliso, FOSCHEK-S, Gabawok NT, DARBOTIN PFS, DECDAN, DECDAN B, DECDAN B Injection, CONSEGNA 30/70 U-200 CART, CONSEGNA R U-200 CART, DECDAN LITE CREAM, GLARITUS CART, GLARITUS DISPO, Glimaday, INOGLA, Livatira, GLARITUS CART and VAL 450. The Company has approximately three studies centers globally and a series of six tremendous-speciality hospitals throughout Maharashtra and Gujarat.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 862 | 854 | 655 | 595 | 679 | 699 | 678 | 644 | 753 | 701 |
| Other Income | 4 | 1 | 14 | 57 | 57 | 2 | 32 | 14 | 24 | 8 |
| Total Income | 866 | 855 | 669 | 652 | 736 | 701 | 710 | 658 | 777 | 709 |
| Total Expenditure | 765 | 742 | 688 | 611 | 636 | 654 | 675 | 628 | 681 | 664 |
| Operating Profit | 101 | 113 | -19 | 41 | 100 | 47 | 35 | 30 | 96 | 45 |
| Interest | 69 | 80 | 86 | 73 | 70 | 83 | 76 | 79 | 76 | 77 |
| Depreciation | 61 | 62 | 59 | 64 | 65 | 66 | 56 | 55 | 55 | 55 |
| Exceptional Income / Expenses | 0 | 0 | -183 | 0 | -195 | -3 | -96 | -14 | 0 | 0 |
| Profit Before Tax | -29 | -29 | -347 | -96 | -230 | -105 | -193 | -118 | -35 | -87 |
| Provision for Tax | -66 | -31 | -36 | -21 | -23 | -3 | 44 | 18 | 38 | -1 |
| Profit After Tax | 37 | 2 | -311 | -75 | -207 | -102 | -237 | -136 | -73 | -86 |
| Adjustments | -3 | -9 | 53 | 8 | 18 | 6 | 29 | 2 | -4 | 3 |
| Profit After Adjustments | 34 | -7 | -258 | -67 | -189 | -96 | -208 | -134 | -77 | -83 |
| Adjusted Earnings Per Share | 2.8 | -0.6 | -17.9 | -4.7 | -13.1 | -6.7 | -14.4 | -9.3 | -5.3 | -5.8 |
| #(Fig in Cr.) | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 5609 | 4830 | 4482 | 4453 | 4015 | 3937 | 3566 | 2844 | 2708 | 3230 | 2651 | 2776 |
| Other Income | 54 | 84 | 67 | 66 | 114 | 177 | 21 | 60 | 132 | 20 | 122 | 78 |
| Total Income | 5663 | 4915 | 4548 | 4519 | 4129 | 4114 | 3587 | 2904 | 2840 | 3250 | 2773 | 2854 |
| Total Expenditure | 3550 | 3851 | 3772 | 3959 | 4002 | 3992 | 3604 | 2746 | 2771 | 2932 | 2550 | 2648 |
| Operating Profit | 2114 | 1064 | 776 | 560 | 127 | 122 | -17 | 158 | 69 | 318 | 223 | 206 |
| Interest | 215 | 83 | 55 | 129 | 225 | 255 | 265 | 276 | 249 | 299 | 302 | 308 |
| Depreciation | 122 | 140 | 145 | 142 | 149 | 150 | 164 | 224 | 246 | 247 | 251 | 221 |
| Exceptional Income / Expenses | 62 | 50 | 0 | 0 | 0 | -358 | 0 | 0 | -142 | -183 | -294 | -110 |
| Profit Before Tax | 1838 | 891 | 575 | 289 | -247 | -641 | -447 | -342 | -568 | -411 | -624 | -433 |
| Provision for Tax | 258 | 48 | 163 | 38 | -21 | 26 | -135 | -204 | -271 | -132 | -3 | 99 |
| Profit After Tax | 1579 | 843 | 413 | 252 | -226 | -667 | -312 | -138 | -297 | -279 | -621 | -532 |
| Adjustments | 15 | -141 | -8 | -1 | 30 | 59 | 117 | 69 | 983 | 35 | 62 | 30 |
| Profit After Adjustments | 1594 | 702 | 405 | 251 | -196 | -608 | -195 | -69 | 686 | -244 | -559 | -502 |
| Adjusted Earnings Per Share | 134.1 | 58.9 | 33.9 | 20.9 | -16.3 | -50.7 | -16.2 | -5.8 | 57.5 | -16.9 | -38.8 | -34.8 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -18% | -2% | -8% | -7% |
| Operating Profit CAGR | -30% | 12% | 13% | -20% |
| PAT CAGR | 0% | 0% | 0% | NAN% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 211% | -1% | 9% | -3% |
| ROE Average | -17% | -12% | -10% | 7% |
| ROCE Average | -6% | -4% | -3% | 5% |
| #(Fig in Cr.) | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 2704 | 3581 | 3715 | 3775 | 3337 | 2852 | 2675 | 2672 | 3376 | 3849 | 3354 |
| Minority's Interest | 0 | 136 | 144 | 465 | 382 | 346 | 330 | 386 | 383 | 353 | 308 |
| Borrowings | 1475 | 1102 | 1185 | 1921 | 3190 | 2173 | 1891 | 1241 | 503 | 355 | 224 |
| Other Non-Current Liabilities | 46 | 59 | 688 | -27 | -39 | -84 | -189 | -46 | -7 | -94 | -246 |
| Total Current Liabilities | 1773 | 1743 | 1773 | 1842 | 1979 | 2692 | 2864 | 3497 | 3121 | 3207 | 3435 |
| Total Liabilities | 5998 | 6622 | 7505 | 7976 | 8849 | 7978 | 7571 | 7749 | 7376 | 7670 | 7075 |
| Fixed Assets | 1990 | 2295 | 2123 | 2809 | 2773 | 2888 | 3058 | 3502 | 3343 | 3462 | 3042 |
| Other Non-Current Assets | 682 | 971 | 1860 | 1215 | 1541 | 1711 | 1698 | 1817 | 1608 | 1619 | 1825 |
| Total Current Assets | 3327 | 3356 | 3522 | 3952 | 4535 | 3380 | 2815 | 2401 | 2281 | 2445 | 1914 |
| Total Assets | 5998 | 6622 | 7505 | 7976 | 8849 | 7978 | 7571 | 7749 | 7376 | 7670 | 7075 |
| #(Fig in Cr.) | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 690 | 1050 | 1102 | 1159 | 663 | 964 | 897 | 397 | 219 | 232 | 370 |
| Cash Flow from Operating Activities | 1532 | 1476 | 355 | 72 | -269 | 68 | 183 | 649 | -287 | 413 | 153 |
| Cash Flow from Investing Activities | 1085 | -852 | -207 | -818 | -687 | 630 | 95 | -156 | 1470 | -201 | -125 |
| Cash Flow from Financing Activities | -2246 | -601 | -76 | 254 | 1254 | -769 | -776 | -680 | -1171 | -71 | -315 |
| Net Cash Inflow / Outflow | 372 | 23 | 73 | -492 | 298 | -71 | -499 | -186 | 12 | 141 | -287 |
| Closing Cash & Cash Equivalent | 1050 | 1102 | 1159 | 665 | 964 | 897 | 397 | 219 | 232 | 370 | 90 |
| # | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 134.06 | 58.93 | 33.89 | 20.91 | -16.32 | -50.67 | -16.2 | -5.76 | 57.47 | -16.94 | -38.82 |
| CEPS(Rs) | 143.1 | 82.51 | 46.72 | 32.82 | -6.43 | -43.09 | -12.31 | 7.17 | -4.27 | -2.22 | -25.69 |
| DPS(Rs) | 5 | 10 | 20 | 0 | 10 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 199.65 | 271.82 | 282.17 | 312.44 | 275.08 | 234.5 | 220.02 | 219.83 | 280.48 | 266.04 | 231.81 |
| Core EBITDA Margin(%) | 36.68 | 20.26 | 15.81 | 11.1 | 0.32 | -1.41 | -1.08 | 3.44 | -1.36 | 5.81 | 2.36 |
| EBIT Margin(%) | 36.56 | 20.14 | 14.05 | 9.4 | -0.55 | -9.8 | -5.09 | -2.33 | -6.88 | -2.18 | -7.54 |
| Pre Tax Margin(%) | 32.73 | 18.42 | 12.82 | 6.5 | -6.16 | -16.29 | -12.52 | -12.03 | -12.25 | -8.01 | -14.6 |
| PAT Margin (%) | 28.13 | 17.43 | 9.19 | 5.65 | -5.63 | -16.94 | -8.74 | -4.85 | -6.41 | -5.44 | -14.53 |
| Cash Profit Margin (%) | 30.3 | 20.32 | 12.43 | 8.84 | -1.92 | -13.14 | -4.15 | 3.03 | -1.1 | -0.62 | -8.66 |
| ROA(%) | 25.78 | 13.36 | 5.84 | 3.25 | -2.69 | -7.93 | -4.01 | -1.8 | -3.93 | -3.71 | -8.42 |
| ROE(%) | 102.78 | 30.04 | 12.49 | 7.07 | -6.42 | -21.81 | -11.43 | -5.22 | -9.92 | -7.77 | -17.32 |
| ROCE(%) | 42.17 | 18.98 | 11.25 | 6.87 | -0.31 | -5.47 | -2.87 | -1.11 | -5.5 | -1.96 | -5.88 |
| Receivable days | 55.81 | 54.33 | 49.71 | 75.93 | 97.55 | 92.57 | 114.46 | 161.49 | 85.04 | 65.29 | 73.25 |
| Inventory Days | 63.29 | 77.43 | 81.88 | 87 | 100.47 | 91.03 | 85.73 | 98.54 | 59.63 | 55.76 | 60.95 |
| Payable days | 122.7 | 120.43 | 136.23 | 134.61 | 128.63 | 115.29 | 160.83 | 263.19 | 255.87 | 232.91 | 293.71 |
| PER(x) | 13.79 | 7.15 | 50.71 | 42.89 | 0 | 0 | 0 | 0 | 6.64 | 0 | 0 |
| Price/Book(x) | 9.26 | 1.55 | 6.09 | 2.87 | 2.41 | 2.85 | 1.86 | 0.72 | 1.36 | 0.99 | 0.66 |
| Dividend Yield(%) | 0.25 | 2.19 | 1.07 | 0 | 1.39 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 4.15 | 1.26 | 4.82 | 2.68 | 2.62 | 2.72 | 2.2 | 1.71 | 2.44 | 1.63 | 1.5 |
| EV/Core EBITDA(x) | 11 | 5.73 | 27.84 | 21.33 | 82.76 | 87.67 | -448.4 | 30.78 | 95.62 | 16.52 | 17.85 |
| Net Sales Growth(%) | 28.94 | -13.89 | -7.22 | -0.63 | -9.85 | -1.94 | -9.43 | -20.24 | -4.78 | 19.28 | -17.93 |
| EBIT Growth(%) | 159.81 | -52.56 | -35.26 | -33.64 | -105.23 | -1662.61 | 52.96 | 63.45 | -381.15 | 64.89 | -187.5 |
| PAT Growth(%) | 427.46 | -46.64 | -51.03 | -39.04 | -189.84 | -195.01 | 53.24 | 55.76 | -115.3 | 6.06 | -122.58 |
| EPS Growth(%) | 364.85 | -56.04 | -42.48 | -38.31 | -178.04 | -210.52 | 68.03 | 64.44 | 1097.71 | -129.48 | -129.1 |
| Debt/Equity(x) | 0.77 | 0.54 | 0.55 | 0.71 | 1.26 | 1.33 | 1.28 | 1.22 | 0.7 | 0.49 | 0.57 |
| Current Ratio(x) | 1.88 | 1.93 | 1.99 | 2.15 | 2.29 | 1.26 | 0.98 | 0.69 | 0.73 | 0.76 | 0.56 |
| Quick Ratio(x) | 1.28 | 1.36 | 1.41 | 1.55 | 1.73 | 0.94 | 0.7 | 0.48 | 0.47 | 0.52 | 0.37 |
| Interest Cover(x) | 9.53 | 11.69 | 11.42 | 3.24 | -0.1 | -1.51 | -0.68 | -0.24 | -1.28 | -0.37 | -1.07 |
| Total Debt/Mcap(x) | 0.09 | 0.38 | 0.1 | 0.25 | 0.52 | 0.47 | 0.69 | 1.68 | 0.51 | 0.49 | 0.85 |
| # | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 67.13 | 67.13 | 65.75 | 63.83 | 60.36 | 59.31 | 58.4 | 55.14 | 54.93 | 51.6 |
| FII | 2.94 | 2.88 | 2.81 | 2.97 | 2.86 | 2.77 | 2.59 | 3.01 | 4.16 | 5.49 |
| DII | 0.1 | 0.1 | 0.11 | 0.16 | 0.23 | 0.23 | 0.19 | 0.23 | 0.32 | 4.85 |
| Public | 29.83 | 29.89 | 31.34 | 33.04 | 36.55 | 37.69 | 38.82 | 41.62 | 40.59 | 38.07 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 7.44 | 9.67 | 9.47 | 9.2 | 8.7 | 8.55 | 8.42 | 7.95 | 7.92 | 7.92 |
| FII | 0.33 | 0.41 | 0.4 | 0.43 | 0.41 | 0.4 | 0.37 | 0.43 | 0.6 | 0.84 |
| DII | 0.01 | 0.01 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.05 | 0.74 |
| Public | 3.31 | 4.31 | 4.51 | 4.76 | 5.26 | 5.43 | 5.59 | 6 | 5.85 | 5.84 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11.08 | 14.41 | 14.41 | 14.41 | 14.41 | 14.41 | 14.41 | 14.41 | 14.41 | 15.34 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
You May Also Know About
